- Home
- CIM vs MDXG Comparison
CIM vs MDXG Comparison
Compare CIM & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CIM | MDXG |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIM | MDXG |
|---|---|---|
| Price | $12.76 | $6.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.25 | $11.00 |
| AVG Volume (30 Days) | 778.6K | ★ 804.1K |
| Earning Date | 02-11-2026 | 10-29-2025 |
| Dividend Yield | ★ 11.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $191,573,000.00 | ★ $393,442,000.00 |
| Revenue This Year | $11.44 | $19.13 |
| Revenue Next Year | $21.50 | $2.11 |
| P/E Ratio | ★ N/A | $25.59 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $9.85 | $5.79 |
| 52 Week High | $15.37 | $9.71 |
Technical Indicators
Market Signals| Indicator | CIM | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 44.36 |
| Support Level | $12.73 | $6.74 |
| Resistance Level | $12.96 | $7.13 |
| Average True Range (ATR) | 0.21 | 0.22 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 41.28 | 13.38 |
Price Performance
Historical ComparisonAbout CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.